PMID: 2506603Jan 1, 1989Paper

Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers

Psychopharmacology
J C Fleishaker, J P Phillips

Abstract

The pharmacokinetics and pharmacodynamics of adinazolam were studied in 15 normal, healthy, non-obese volunteers. Placebo capsules and capsules containing 20, 40, and 60 mg adinazolam mesylate were administered as single oral doses in a randomized, 4-way crossover design. Plasma concentrations of adinazolam and mono-N-desmethyladinazolam (NDMAD) were determined by HPLC. Psychomotor performance and memory tests were performed and the degree of sedation assessed at designated times following drug administration. Adinazolam and NDMAD pharmacokinetics were linear throughout the dosage range studied. The ratio of NDMAD to adinazolam area under the curve was approximately 4:1. Dose-related decrements in psychomotor performance and memory were observed up to 8 h after dosing (P less than 0.025 in all cases). Psychomotor performance decrements correlated more closely with NDMAD plasma concentrations than with adinazolam concentrations. These results suggest that NDMAD is responsible for a significant degree of the sedative and psychomotor effects observed after the administration of adinazolam.

References

Jun 1, 1991·Journal of Clinical Pharmacology·P D KrobothR B Smith
May 1, 1989·Pharmaceutical Research·J C FleishakerR B Smith
Aug 1, 1986·The Journal of Pharmacy and Pharmacology·V H SethyJ S Day
Mar 1, 1988·Clinical Pharmacology and Therapeutics·P D KrobothR J Erb
Dec 1, 1987·Journal of Clinical Pharmacology·R B SmithP D Varner
Sep 1, 1987·Biopharmaceutics & Drug Disposition·J G WagnerG J Szpunar
Jan 1, 1983·British Journal of Clinical Pharmacology·W H ZieglerM Eckert
Aug 1, 1984·The Journal of Pharmacy and Pharmacology·V H SethyE G Daniels
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Sep 1, 1955·Journal of Abnormal Psychology·J E DOPPELT, W L WALLACE
Apr 1, 1986·Pharmaceutical Research·G S DuchateauF W Merkus

❮ Previous
Next ❯

Citations

Apr 16, 2005·Journal of Clinical Pharmacology·Karthik VenkatakrishnanDavid J Greenblatt
May 5, 2017·Drug Testing and Analysis·Kieran R ManchesterPeter D Maskell
May 28, 2020·Frontiers in Pharmacology·Daniela Fukushiro-LopesSaverio Gentile
Jul 3, 2021·Pharmaceuticals·Pietro BrunettiFrancesco Paolo Busardò

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.